The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Direct Angiotensin II Type 2 Receptor Stimulation Acts Anti-Inflammatory Through Epoxyeicosatrienoic Acid and Inhibition of Nuclear Factor κB
Abstract
Angiotensin II type 2 (AT 2 ) receptors can be regarded as an endogenous repair system, because the AT 2 receptor is upregulated in tissue damage and mediates tissue protection. A potential therapeutic use of this system has only recently come within reach through synthesis of the first selective, orally active, nonpeptide AT 2 receptor agonist, compound 21 (C21; dissociation constant for AT 2 receptor: 0.4 nM; dissociation constant for angiotensin II type 1 receptor: >10 000 nM). This study tested AT 2 receptor stimulation with C21 as a potential future therapeutic approach for the inhibition of proinflammatory cytokines and of nuclear factor κB. C21 dose-dependently (1 nM to 1 μmol/L) reduced tumor necrosis factor-α–induced interleukin 6 levels in primary human and murine dermal fibroblasts. AT 2 receptor specificity was controlled for by inhibition with the AT 2 receptor antagonist PD123319 and by the absence of effects in AT 2 receptor–deficient cells. AT 2 receptor–coupled signaling leading to reduced interleukin 6 levels involved inhibition of nuclear factor κB, activation of protein phosphatases, and synthesis of epoxyeicosatrienoic acid. Inhibition of interleukin 6 promoter activity by C21 was comparable in strength to inhibition by hydrocortisone. C21 also reduced monocyte chemoattractant protein 1 and tumor necrosis factor-α in vitro and in bleomycin-induced toxic cutaneous inflammation in vivo. This study is the first to show the anti-inflammatory effects of direct AT 2 receptor stimulation in vitro and in vivo by the orally active, nonpeptide AT 2 receptor agonist C21. These data suggest that pharmacological AT 2 receptor stimulation may be an orally applicable future therapeutic approach in pathological settings requiring the reduction of interleukin 6 or inhibition of nuclear factor κB.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer
Naugler, W. E., & Karin, M. (2008) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2007.12.007 · Cited by 730
Cited by
Classical Renin‐Angiotensin System in Kidney Physiology
Sparks, M. A., Crowley, S. D., Gurley, S. B., Mirotsou, M., & Coffman, T. M. (2014) · Comprehensive Physiology · doi:10.1002/cphy.c130040 · Cited by 521
Li, X. C., Zhang, J., & Zhuo, J. L. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.06.005 · Cited by 435
Cardiac fibrosis: new insights into the pathogenesis
Ma, Z.-G., Yuan, Y.-P., Wu, H.-M., Zhang, X., & Tang, Q.-Z. (2018) · International Journal of Biological Sciences · doi:10.7150/ijbs.28103 · Cited by 331
The Angiotensin AT2 Receptor: From a Binding Site to a Novel Therapeutic Target
Steckelings, U. M., Widdop, R. E., Sturrock, E. D., Lubbe, L., Hussain, T., Kaschina, E., Unger, T., Hallberg, A., Carey, R. M., & Sumners, C. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000281 · Cited by 97
Self-citationHajjar, I., Hart, M., Chen, Y.-L., Mack, W., Milberg, W., Chui, H., & Lipsitz, L. (2012) · Archives of Internal Medicine · doi:10.1001/archinternmed.2011.1391 · Cited by 84
Metadata
- Authors
- Rompe, F., Artuc, M., Hallberg, A., Alterman, M., Ströder, K., Thöne-Reineke, C., Reichenbach, A., Schacherl, J., Dahlöf, B., Bader, M., Alenina, N., Schwaninger, M., Zuberbier, T., Funke-Kaiser, H., Schmidt, C., Schunck, W.-H., Unger, T., & Steckelings, U. M.
- Venue
- Hypertension
- Published
- 2010-04
- Volume
- 55
- Issue
- 4
- Pages
- 924-931
- ISSN
- 0194-911X (ISSN-L)
- 1524-4563
- OpenAlex
- W2168535680
- Cited by
- 208
- References
- 1
- FWCI
- 12.47
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Direct Angiotensin II Type 2 Receptor Stimulation Acts Anti-Inflammatory Through Epoxyeicosatrienoic Acid and Inhibition of Nuclear Factor κB. https://app.cochat.ai/papers/10.1161/hypertensionaha.109.147843
- The paper
- Rompe, F., Artuc, M., Hallberg, A., Alterman, M., Ströder, K., Thöne-Reineke, C., Reichenbach, A., Schacherl, J., Dahlöf, B., Bader, M., Alenina, N., Schwaninger, M., Zuberbier, T., Funke-Kaiser, H., Schmidt, C., Schunck, W.-H., Unger, T., & Steckelings, U. M. (2010). Direct Angiotensin II Type 2 Receptor Stimulation Acts Anti-Inflammatory Through Epoxyeicosatrienoic Acid and Inhibition of Nuclear Factor κB. Hypertension. https://doi.org/10.1161/hypertensionaha.109.147843
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.